New drug combo aims to control rare lung cancer
NCT ID NCT07234058
First seen Nov 18, 2025 · Last updated May 23, 2026 · Updated 24 times
Summary
This study tests whether adding an experimental immunotherapy (fianlimab) to standard immunotherapy (cemiplimab) plus chemotherapy can help control pleural mesothelioma, a rare and aggressive lung cancer. About 126 people who have not yet been treated will receive one of two treatment combinations. The goal is to see if the disease can be kept from growing for at least 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLEURAL MESOTHELIOMAS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aix-Pertuis - CHI
Aix-en-Provence, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Amiens - CHU
Amiens, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Angers - CHU
Angers, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Avignon - CH
Avignon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Besançon - CHU
Besançon, 75009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Bordeaux - CHU
Pessac, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Bordeaux - Institut Bergonié
Bordeaux, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Boulogne - APHP Ambroise Paré
Boulogne-Billancourt, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Caen - CHU
Caen, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Clermont-Ferrand - CHU
Clermont-Ferrand, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Clermont-Ferrand - Centre Jean Perrin
Clermont-Ferrand, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Créteil - CHI
Créteil, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dijon - Centre Georges-François Leclerc
Dijon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Grenoble - CHU
Grenoble, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
La Roche-Sur-Yon - CHD Vendée
La Roche-sur-Yon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Le Mans - CHG
Le Mans, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lille - CHU
Lille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lyon - HCL
Pierre-Bénite, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Marseille - APHM Nord
Marseille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Marseille - Hôpital Européen
Marseille, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Montpellier - CHU
Montpellier, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mulhouse - GHRMSA
Mulhouse, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nantes - Hôpital Laennec
Nantes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Nantes - Institut de Cancérologie de l'Ouest
Saint-Herblain, 75009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Paris - APHP Bichat
Paris, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Paris - APHP Cochin
Paris, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Reims - Institut Godinot
Reims, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Rennes - CHU
Rennes, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Saint-Nazaire - Clinique Mutualiste de l'Estuaire
Saint-Nazaire, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Strasbourg - Nouvel Hôpital Civil
Strasbourg, 75009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Toulon - CHI
Toulon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Toulon - Sainte Anne HIA
Toulon, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Toulouse - CHU
Toulouse, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tours - CHU
Tours, 75009, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Vandoeuvre-lès-Nancy - Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Villefranche sur Saône - CH
Villefranche-sur-Saône, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Villejuif - Gustave Roussy
Villejuif, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.